Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

NC-2500 is selected for clinical development in gout-related hyperuricemia

Sep. 7, 2010

Banyu Pharmaceutical discloses novel inhibitors of MGAT2

Sep. 7, 2010

GSK responds to article on rosiglitazone

Sep. 7, 2010

Levitra orodispersible tablet is approved in Europe for erectile dysfunction

Sep. 6, 2010

MSD and Faes Farma to market sitagliptin and sitagliptin/metformin in Spain

Sep. 6, 2010

Eisai launches Glufast in China for type 2 diabetes

Sep. 6, 2010

INT-007 is bioequivalent to branded tablet for erectile dysfunction

Sep. 6, 2010

New MCH1 receptor antagonists claimed by sanofi-aventis

Sep. 6, 2010

Orexigen and Takeda to co-commercialize Contrave in North America

Sep. 3, 2010

LG Life Sciences discloses new xanthine oxidase inhibitors

Sep. 3, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...